Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Cuzick

Showing results (321-330 of 367) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2008
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialMitch Dowsett, Craig Allred, Jill Knox, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 15, 2012
Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer preventionD Gareth R Evans, Jane Warwick, Susan M Astley, et al.
The Lancet. Oncology|January 22, 2010
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialGuglielmo Ronco, Paolo Giorgi-Rossi, Francesca Carozzi, et al.
Breast Cancer Research : BCR|February 7, 2018
A comparison of five methods of measuring mammographic density: a case-control studySusan M Astley, Elaine F Harkness, Jamie C Sergeant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reductionKala Visvanathan, Rowan T Chlebowski, Patricia Hurley, et al.
International Journal of Cancer|July 27, 2010
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservativelyM Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2013
Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrenceMichael D Allen, Gareth J Thomas, Sarah Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guidelineKala Visvanathan, Patricia Hurley, Elissa Bantug, et al.
Archives of Pathology & Laboratory Medicine|November 14, 2019
Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST TerminologyPhilip E Castle, Rachael Adcock, Jack Cuzick, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Pageof 37

Showing results (321-330 of 367) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2008
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialMitch Dowsett, Craig Allred, Jill Knox, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 15, 2012
Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer preventionD Gareth R Evans, Jane Warwick, Susan M Astley, et al.
The Lancet. Oncology|January 22, 2010
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialGuglielmo Ronco, Paolo Giorgi-Rossi, Francesca Carozzi, et al.
Breast Cancer Research : BCR|February 7, 2018
A comparison of five methods of measuring mammographic density: a case-control studySusan M Astley, Elaine F Harkness, Jamie C Sergeant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reductionKala Visvanathan, Rowan T Chlebowski, Patricia Hurley, et al.
International Journal of Cancer|July 27, 2010
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservativelyM Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2013
Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrenceMichael D Allen, Gareth J Thomas, Sarah Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guidelineKala Visvanathan, Patricia Hurley, Elissa Bantug, et al.
Archives of Pathology & Laboratory Medicine|November 14, 2019
Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST TerminologyPhilip E Castle, Rachael Adcock, Jack Cuzick, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Pageof 37